NewsMarkets

Health

FDA Approves Bayer's Sunharbo for Secondary Stroke Prevention

The FDA has approved asundexian, marketed as Sunharbo, to reduce the risk of recurrent ischemic stroke in patients.

2 publishers · 2 articles · first seen 10 Nov 2026 · updated 5d ago

Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made

This story has stopped developing; this page is its permanent record. More from that day

The story so far

2 publishers have covered this in 2 articles since 10 Nov 2026. Quartz published first, on 10 November at 13:00 UTC; MedPageToday.com - medical news for physicians followed 6h 18m later. The most recent article, from MedPageToday.com - medical news for physicians, appeared on 10 November at 19:18 UTC.

Outlets reporting it: Quartz, MedPageToday.com - medical news for physicians.

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention MedPageToday.com - medical news for physicians
  2. Bayer won U.S. FDA approval for a first-in-class stroke blood thinner Quartz

In this story

  • FDA
  • Bayer
  • asundexian
  • Sunharbo
Embed this story

Paste this into any web page to show the live odds, with a link back here.